News

You are here

Jul 08, 2015

Roger Prades, Iproteos CSO, will be attending the 28th ECNP Congress of Applied and Translational Neuroscience, which will take place in Amsterdam from the 29th of August till the 1st of September. The good news is that his poster has been selected for a short oral presentation, since his abstract is among the 18 with the highest score. Taking into account that in the previous ECNP Congress, which was held on Berlin, there were more than 5,500 attendees, it is an honor for Iproteos to have been selected for the oral presentation.

Jun 08, 2015

The network ECMED has a brand new webpage (http://www.ecmed-itn.eu). ECMED is a consortium formed by 11 organizations (9 public centres and 2 companies) aimed to design, validate and bring into practice new innovative therapeutic strategies against epilepsy. As well, the consortium seeks to develop a diagnostic approach for the management of this disease. The consortium's projects are co-funded by the European Union’s Horizon 2020 research and innovation programme under a Marie Sklodowska-Curie grant (No. 645881).

May 29, 2015

On Tuesday 16th of June 2015, Iproteos will celebrate an Ordinary General Meeting. More information is given in the link below. El martes 16 de Enero de 2015, Iproteos celebrará una Junta General Ordinaria. Se puede encontrar toda la información necesaria en el siguiente enlace: CONVOCATORIA JUNTA GENERAL IPROTEOS 16 DE JUNIO 2015

May 05, 2015

The biotech Iproteos participates in a project co-funded by the European Union’s Horizon 2020 research and innovation programme under a Marie Sklodowska-Curie grant (No. 645881). The project, called ECMED (Extracellular Matrix in Epileptogenesis), is aimed to design, validate and bring into practice new innovative therapeutic strategies to further the development of a treatment and a diagnostic approach for the management of epilepsy. It has a duration of three years and a budget of € 3.5 million. Around 50 million people worldwide suffer from epilepsy, according to WHO.

Apr 28, 2015

JOB TITLE:                   Early Stage Researcher (ESR)                                                               Company:                   Iproteos Supervised by:      Dr. Teresa Tarragó Area of study:         This position is funded by a Marie Curie Initial Training Network Initiative.

Feb 10, 2015

Roger Prades, Iproteos CSO, is the first author of an article published this January at Angewandte Chemie reporting a novel peptide capable of overcoming the blood-brain barrier. The work has been possible through the collaboration of a team composed by scientists at IRB Barcelona, RCSI, ISD, INA and UB. The BBB-shuttle is a retro-enantio peptide that is protease-resistant, non-toxic and has the ability of transporting cargos of distinct sizes and types across this barrier. It targets the transferrin receptor but it does not compete with transferrin. Therefore, the peptide reported by Dr.